News and Announcements
SUDA Business Development Update and AGM Presentation
- Published November 17, 2015 4:12PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
17th November 2015
SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that it is on track with its business development goals to sign licensing deals in FY2015/16 and to secure philanthropic funding for a second Phase III study of ArTiMist™ in paediatric malaria.
In early November, the management team attended the BIO-Europe international partnering conference, which was held in Munich, Germany; and also the Northern Australian Investment Forum on tropical diseases, which took place in Darwin. These events provided excellent opportunities for the Company to further advance its business development activities.
SUDA’s business development team met with 41 companies at the BIO-Europe event, comprising 24 first-time meetings and 17 ongoing dialogues with prospective partners. The most advanced discussions are at the stage of financial negotiation and span several of the companies’ first-in-class oral sprays in various territories.
To read the full announcement, please click on the link below.
To view the presentation, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
